Meta-Analysis of Effect of Statin Treatment on Risk of Sudden Death

American Journal of Cardiology

Volumn 100, Issue 11, 2007, Pages 1644-1650

  Levantesi, Giacomo ^a   Scarano, Marco ^a   Marfisi, RosaMaria ^a   Borrelli, Giovanna ^a   Rutjes, Anne W S ^a   Silletta, Maria Giuseppina ^a   Tognoni, Gianni ^a   Marchioli, Roberto ^a  

^a Consorzio Mario Negri Sud ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CHOLESTEROL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PRAVASTATIN; SIMVASTATIN;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG EFFECT; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; MEDLINE; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; STANDARD; STATISTICAL SIGNIFICANCE; SUDDEN DEATH; SYSTEMATIC REVIEW;

CARDIOVASCULAR DISEASES; DEATH, SUDDEN; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TREATMENT OUTCOME;

EID: 36248964633     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.07.015     Document Type: Article

References (34)

1. Robinson J.G., Smith B., Maheshwari N., and Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction?. A meta-regression analysis. J Am Coll Cardiol 46 (2005) 1855-1862
2. Ross S.D., Allen I.E., Connelly J.E., Korenblat B.M., Smith M.E., Bishop D., and Luo D. Clinical outcomes in statin treatment trials: a meta-analysis. Arch Intern Med 159 (1999) 1793-1802
3. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 109 (2004) III39-III43
4. Nissen S.E. High-dose statins in acute coronary syndromes: not just lipid levels. JAMA 292 (2004) 1365-1367
5. Scandinavian Simvastatin Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
6. Long-Term Intervention With Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339 (1998) 1349-1357
7. De Sutter J., Tavernier R., De Buyzere M., Jordaens L., and De Backer G. Lipid lowering drugs and recurrences of life-threatening ventricular arrhythmias in high-risk patients. J Am Coll Cardiol 36 (2000) 766-772
8. Lorenz H., Junger C., Seidl K., Gitt A., Schneider S., Schiele R., Wienbergen H., Winkler R., Gottwik M., Delius W., Senges J., and Rauch B. Do statins influence the prognostic impact of non-sustained ventricular tachycardia after ST-elevation myocardial infarction?. Eur Heart J 26 (2005) 1078-1085
9. Mitchell L.B., Powell J.L., Gillis A.M., Kehl V., and Hallstrom A.P. Are lipid-lowering drugs also antiarrhythmic drugs?. An analysis of the Antiarrhythmics versus Implantable Defibrillators (AVID) trial. J Am Coll Cardiol 42 (2003) 81-87
10. Vyas A.K., Guo H., Moss A.J., Olshansky B., McNitt S.A., Hall W.J., Zareba W., Steinberg J.S., Fischer A., Ruskin J., and Andrews M.L. Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol 47 (2006) 76-773
11. The Pravastatin Multinational Study Group for Cardiac Risk Patients. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. Am J Cardiol 72 (1993) 1031-1037
12. The Scandinavian Simvastatin Survival Study Group. Design and baseline results of the Scandinavian Simvastatin Survival Study of patients with stable angina and/or previous myocardial infarction. Am J Cardiol 71 (1993) 393-400
13. Pedersen T.R., Olsson A.G., Faergeman O., Kjekshus J., Wedel H., Berg K., Wilhelmsen L., Haghfelt T., Thorgeirsson G., Pyorala K., et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 97 (1998) 1453-1460
14. MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 344 (1994) 633-638
15. Pitt B., Ellis S.G., Mancini G.B., Rosman H.S., and McGovern M.E. Design and recruitment in the United States of a multicenter quantitative angiographic trial of pravastatin to limit atherosclerosis in the coronary arteries (PLAC I). Am J Cardiol 72 (1993) 31-35
16. Pitt B., Mancini G.B., Ellis S.G., Rosman H.S., Park J.S., and McGovern M.E. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation. J Am Coll Cardiol 26 (1995) 1133-1139
17. Bertrand M.E., McFadden E.P., Fruchart J.C., Van Belle E., Commeau P., Grollier G., Bassand J.P., Machecourt J., Cassagnes J., Mossard J.M., et al., The PREDICT Trial Investigators. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. Prevention of Restenosis by Elisor after Transluminal Coronary Angioplasty. J Am Coll Cardiol 30 (1997) 863-869
18. The LIPID Study Group. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet 359 (2002) 1379-1387
19. GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico). Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge?. Ital Heart J 1 (2000) 810-820
20. Liem A.H., van Boven A.J., Veeger N.J., Withagen A.J., Robles de Medina R.M., Tijssen J.G., and van Veldhuisen D.J. Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial. Eur Heart J 23 (2002) 1931-1937
21. Bae J.H., Bassenge E., Kim K.Y., Synn Y.C., Park K.R., and Schwemmer M. Effects of low-dose atorvastatin on vascular responses in patients undergoing percutaneous coronary intervention with stenting. J Cardiovasc Pharmacol Ther 9 (2004) 185-192
22. Wanner C., Krane V., Marz W., Olschewski M., Asmus H.G., Kramer W., Kuhn K.W., Kutemeyer H., Mann J.F., Ruf G., and Ritz E. Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D Study): demographic and baseline characteristics. Kidney Blood Press Res 27 (2004) 259-266
23. Wanner C., Krane V., Marz W., Olschewski M., Mann J.F., Ruf G., and Ritz E. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353 (2005) 238-248
24. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., Kirby A., Sourjina T., Peto R., Collins R., and Simes R. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
25. Chiu J.H., Abdelhadi R.H., Chung M.K., Gurm H.S., Marrouche N.F., Saliba W.I., Natale A., and Martin D.O. Effect of statin therapy on risk of ventricular arrhythmia among patients with coronary artery disease and an implantable cardioverter-defibrillator. Am J Cardiol 95 (2005) 490-491
26. De Sutter J., De Bacquer D., Jordaens L., et al. Intensive lipid-lowering therapy and ventricular arrhythmias in patients with coronary artery disease and internal cardioverter defibrillators. Program and abstracts from the Heart Rhythm Society 2006 Scientific Sessions (2006), Massachusetts, Boston
27. Goldberger J.J., Subacius H., Schaechter A., Howard A., Berger R., Shalaby A., Levine J., and Kadish A.H. Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol 48 (2006) 1228-1233
28. Grundy S.M., Cleeman J.I., Merz C.N., Brewer Jr. H.B., Clark L.T., Hunninghake D.B., Pasternak R.C., Smith Jr. S.C., and Stone N.J. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
29. Kayikcioglu M., Can L., Evrengul H., Payzin S., and Kultursay H. The effect of statin therapy on ventricular late potentials in acute myocardial infarction. Int J Cardiol 90 (2003) 63-72
30. Chen J., Shen H., Nagasawa Y., Mitsui K., Tsurugi K., and Hashimoto K. Pravastatin inhibits arrhythmias induced by coronary artery ischemia in anesthetized rats. J Pharmacol Sci 103 (2007) 317-322
31. -/- mice in vivo. Circulation 107 (2003) 2480-2486
32. Pliquett R.U., Cornish K.G., Peuler J.D., and Zucker I.H. Simvastatin normalizes autonomic neural control in experimental heart failure. Circulation 107 (2003) 2493-2498
33. AVID Investigators. Causes of death in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial. J Am Coll Cardiol 34 (1999) 1552-1559
34. Mehta D., Curwin J., Gomes J.A., and Fuster V. Sudden death in coronary artery disease: acute ischemia versus myocardial substrate. Circulation 96 (1997) 3215-3223